From the Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis.
Stroke. 2013 Dec;44(12):3571-2. doi: 10.1161/STROKEAHA.113.002567. Epub 2013 Oct 17.
A high rate of postprocedure complications in the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) trial has raised concerns whether such results are representative of intracranial stent placement in actual routine practice.
Using the Nationwide Inpatient Sample from 2008 to 2010, patients with cerebral ischemic events treated with intracranial stent as part of a clinical trial or outside the trial were identified. The composite end point (postoperative stroke, cardiac complications, and mortality) was reported.
Of the 3447 patients who underwent intracranial stent placement, 223 patients (6.5%) were enrolled in a clinical trial. The rate of composite end point was higher in patients treated outside clinical trials compared with those treated within clinical trials (14.2% versus 4.5%; P=0.1). The proportion of patients discharged to home was higher in those treated in clinical trials (76.8% versus 49.6%; P=0.001).
Intracranial stent placement procedures outside a clinical trial have higher rates of postoperative stroke, cardiac complication, and mortality.
支架置入术与强化药物治疗颅内动脉狭窄(SAMMPRIS)试验中较高的术后并发症发生率引起了人们的担忧,即这些结果是否能代表颅内支架置入术在实际常规实践中的情况。
利用 2008 年至 2010 年全国住院患者样本,确定了接受颅内支架治疗作为临床试验一部分或临床试验之外的脑缺血事件患者。报告了复合终点(术后卒中、心脏并发症和死亡率)。
在 3447 例接受颅内支架置入术的患者中,223 例(6.5%)患者入组了临床试验。与临床试验内治疗的患者相比,临床试验外治疗的患者复合终点发生率更高(14.2%比 4.5%;P=0.1)。临床试验内治疗的患者出院回家的比例更高(76.8%比 49.6%;P=0.001)。
临床试验外的颅内支架置入术术后卒中、心脏并发症和死亡率较高。